Current Treatments
BETASERON® (interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis

AVONEX® (Interferon beta-1a) is a 166 amino acid glycoprotein with a predicted molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of AVONEX® is identical to that of natural human interferon beta.

COPAXONE is the brand name for glatiramer acetate (formerly known as copolymer-1). Glatiramer acetate, the active ingredient of COPAXONE, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000 – 9,000 daltons. Glatiramer acetate is identified by specific antibodies.

Rebif® (interferon beta-1a) is a purified 166 amino acid glycoprotein with a molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of Rebif® is identical to that of natural fibroblast derived human interferon beta. Natural interferon beta and interferon beta-1a (Rebif®) are glycosylated with each containing a single N-linked complex carbohydrate moiety.

Tysabri is a monoclonal antibody that affects the actions of the body's immune system. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. Tysabri is used to treat relapsing forms of multiple sclerosis. 		Gilenya™ is a new class of medication called a phingosine 1-phosphate receptormodulator, which is thought to act by retaining certain white blood cells (lympohcytes) in the lymph nodes, thereby preventing those cells from crossing the blood-brain barrier into the central nervous system (CNS). Preventing the entry of these cells into the CNS reduces inflammatory damage to nerve cells.

Early Symptoms
The most common early symptoms of MS include:
* Tingling * Numbness
* Loss of balance
* Weakness in one or more limbs
* Blurred or double vision

Less common symptoms of MS may include
* Slurred speech
* Sudden onset of paralysis
* Lack of coordination
* Cognitive difficulties
Listed above, the early symptoms. I tend to be a poster child for these. The symptoms that occur later on are too numerous just to list. There will be a link included that will get you to a site where these symptoms are listed and explained. Keep in mind that someone may have some of these or many of these, there is no way to tell.
Multiple sclerosis statistics show that approximately 250,000 to 350,000 people in the United States have been diagnosed with this disease. The life expectancy for people with multiple sclerosis is nearly the same as for those without MS. Because of this, multiple sclerosis statistics place the annual cost of MS in the United States in the billions of dollars. MS is five times more prevalent in temperate climates -- such as those found in the northern United States, Canada, and Europe -- than in tropical regions. Furthermore, the age of 15 seems to be significant in terms of risk for developing the disease. Some studies indicate that a person moving from a high-risk (temperate) to a low-risk (tropical) area before the age of 15 tends to adopt the risk (in this case, low) of the new area and vice versa. Other studies suggest that people moving after age 15 maintain the risk of the area where they grew up.

Monday, August 2, 2010

Call Today to Support Medicaid Assistance

National MS Society, Greater New England Chapter
to me

show details 3:48 PM (40 minutes ago)

Images are not displayed.
Display images below - Always display images from advocacygne@nmss.org
2009ActionAlert_2





We need some help with Senator Brown from MA and both Maine Senators Collins & Snowe.

The Senate early this evening will take an important vote on a bill that would extend federal assistance to state Medicaid programs. An enhanced federal medical assistance percentage (FMAP) was originally included in the Recovery Act to help save jobs and save critical safety net health services. Since the Senate floor schedule is very full, tonight’s vote is seen as the last opportunity to extend the Medicaid assistance. Medicaid assistance currently runs through December 31, 2010; the legislation that will be voted on would extend it and phase it out though June 30, 2011.

It is unclear whether the Senate has the votes right now to pass the bill. Senator Brown’s (MA), Collins’ (ME) and Snowe’s (ME) support is critical. Please make phone calls to these Senators’ offices today. We have provided a toll-free number and talking points below. The vote is tonight, so phone calls must be made today. Thank you for your speedy attention to this matter!

Toll-free Phone Number: (888) 340-6521

Talking Points:

* As a constituent, I urge Senator [Brown (MA) or Collins (ME) or Snowe (ME)] to SUPPORT THE MEDICAID AND EDUCATIONS JOBS AMENDMENT TO H.R. 1586
* Medicaid provides critical health coverage to nearly 50 million Americans including nearly 9 million non-elderly persons living with disabilities. It is our safety net.
* As unemployment rises in the troubled economic times, Medicaid enrollment rises at the same time as state budgets are extremely strained.
* Medicaid fiscal relief included in the Recovery Act prevented harmful budget cuts, saved jobs and protected healthcare coverage of many in need.
* Medicaid assistance to states must continue.
* Please urge Senator [Brown (MA) or Collins (ME) or Snowe (ME)] to SUPPORT THE MEDICAID AND EDUCATIONS JOBS AMENDMENT TO H.R. 1586.



National Multiple Sclerosis Society
Greater New England Chapter
101A First Avenue, Suite 6
Waltham, MA 02451-1115
tel: 1 800-344-4867
fax: 1 781-890-2089
MSnewengland.org
Advocacy Icon Jpg

Early and ongoing treatment with an FDA-approved therapy can ma
Posted by Steve at Monday, August 02, 2010

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

About Me

My photo
North Grafton, Massachusetts, United States
Well-educated, disabled at this point with Multiple Sclerosis. I am very glad that I was able to do the things that I have been able to do over the years. had to change the picture, this one's more realistic.